Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.83
BIO's Cash to Debt is ranked higher than
50% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. BIO: 1.83 )
Ranked among companies with meaningful Cash to Debt only.
BIO' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.81 Max: 1.83
Current: 1.83
0.04
1.83
Equity to Asset 0.68
BIO's Equity to Asset is ranked higher than
66% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. BIO: 0.68 )
Ranked among companies with meaningful Equity to Asset only.
BIO' s Equity to Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.53 Max: 0.68
Current: 0.68
0.33
0.68
Interest Coverage 6.09
BIO's Interest Coverage is ranked lower than
80% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. BIO: 6.09 )
Ranked among companies with meaningful Interest Coverage only.
BIO' s Interest Coverage Range Over the Past 10 Years
Min: 2.77  Med: 5.04 Max: 7.69
Current: 6.09
2.77
7.69
F-Score: 6
Z-Score: 4.01
M-Score: -2.51
WACC vs ROIC
6.88%
4.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 6.92
BIO's Operating margin (%) is ranked higher than
62% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. BIO: 6.92 )
Ranked among companies with meaningful Operating margin (%) only.
BIO' s Operating margin (%) Range Over the Past 10 Years
Min: 6.9  Med: 10.92 Max: 14.74
Current: 6.92
6.9
14.74
Net-margin (%) 4.79
BIO's Net-margin (%) is ranked higher than
62% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.51 vs. BIO: 4.79 )
Ranked among companies with meaningful Net-margin (%) only.
BIO' s Net-margin (%) Range Over the Past 10 Years
Min: 3.65  Med: 7.18 Max: 9.63
Current: 4.79
3.65
9.63
ROE (%) 3.91
BIO's ROE (%) is ranked higher than
59% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. BIO: 3.91 )
Ranked among companies with meaningful ROE (%) only.
BIO' s ROE (%) Range Over the Past 10 Years
Min: 3.7  Med: 9.64 Max: 13.98
Current: 3.91
3.7
13.98
ROA (%) 2.62
BIO's ROA (%) is ranked higher than
63% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.30 vs. BIO: 2.62 )
Ranked among companies with meaningful ROA (%) only.
BIO' s ROA (%) Range Over the Past 10 Years
Min: 2.28  Med: 5.14 Max: 6.83
Current: 2.62
2.28
6.83
ROC (Joel Greenblatt) (%) 14.48
BIO's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -10.22 vs. BIO: 14.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 14.48  Med: 28.07 Max: 36.51
Current: 14.48
14.48
36.51
Revenue Growth (3Y)(%) -1.70
BIO's Revenue Growth (3Y)(%) is ranked lower than
64% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. BIO: -1.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BIO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.7  Med: 8.6 Max: 21
Current: -1.7
-1.7
21
EBITDA Growth (3Y)(%) -10.80
BIO's EBITDA Growth (3Y)(%) is ranked lower than
72% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. BIO: -10.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BIO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.9  Med: 11 Max: 40.2
Current: -10.8
-10.9
40.2
EPS Growth (3Y)(%) -12.70
BIO's EPS Growth (3Y)(%) is ranked lower than
64% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. BIO: -12.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.8  Med: 10.7 Max: 76.3
Current: -12.7
-25.8
76.3
» BIO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BIO Guru Trades in Q3 2015

Ray Dalio 2,978 sh (New)
Steven Cohen 73,700 sh (New)
George Soros 2,200 sh (New)
Jim Simons 89,520 sh (+50.45%)
Private Capital 14,677 sh (unchged)
First Pacific Advisors 1,500 sh (unchged)
Mario Gabelli 68,200 sh (-1.02%)
Ken Fisher 275,519 sh (-3.74%)
Joel Greenblatt 115,771 sh (-6.85%)
NWQ Managers 443,605 sh (-10.84%)
John Rogers 1,000,161 sh (-10.94%)
Chuck Royce 323,890 sh (-11.02%)
Pioneer Investments 16,205 sh (-16.84%)
Paul Tudor Jones 3,444 sh (-41.93%)
» More
Q4 2015

BIO Guru Trades in Q4 2015

Paul Tudor Jones 3,600 sh (+4.53%)
Pioneer Investments 16,639 sh (+2.68%)
John Rogers 1,005,947 sh (+0.58%)
Ray Dalio Sold Out
George Soros Sold Out
First Pacific Advisors Sold Out
Ken Fisher 274,634 sh (-0.32%)
Mario Gabelli 67,000 sh (-1.76%)
Private Capital 14,402 sh (-1.87%)
NWQ Managers 425,876 sh (-4.00%)
Jim Simons 81,500 sh (-8.96%)
Steven Cohen 58,800 sh (-20.22%)
Joel Greenblatt 91,287 sh (-21.15%)
Chuck Royce 215,930 sh (-33.33%)
» More
Q1 2016

BIO Guru Trades in Q1 2016

Jim Simons 144,900 sh (+77.79%)
Private Capital Sold Out
Steven Cohen Sold Out
John Rogers 1,004,492 sh (-0.14%)
Mario Gabelli 66,500 sh (-0.75%)
NWQ Managers 422,546 sh (-0.78%)
Ken Fisher 269,075 sh (-2.02%)
Pioneer Investments 16,205 sh (-2.61%)
Paul Tudor Jones 3,335 sh (-7.36%)
Chuck Royce 192,930 sh (-10.65%)
Joel Greenblatt 67,705 sh (-25.83%)
» More
Q2 2016

BIO Guru Trades in Q2 2016

Steven Cohen 38,800 sh (New)
Mariko Gordon 20,392 sh (New)
NWQ Managers 503,466 sh (+19.15%)
Ken Fisher 281,583 sh (+4.65%)
Pioneer Investments 16,205 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
John Rogers 980,851 sh (-2.35%)
Mario Gabelli 63,200 sh (-4.96%)
Chuck Royce 178,630 sh (-7.41%)
Jim Simons 47,100 sh (-67.49%)
» More
» Details

Insider Trades

Latest Guru Trades with BIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:ICLR, NYSE:CRL, NAS:CPHD, NYSE:ALR, NAS:VWR, NAS:PRXL, NAS:BRKR, OTCPK:BMXMF, NYSE:PKI, NAS:PRAH, NAS:QGEN, OTCPK:CZMWY, NAS:INCR, NAS:NEOG, OTCPK:ERFSF, NAS:EXAS, NAS:DXCM, NAS:MYGN, NAS:AXDX, NAS:KANG » details
Traded in other countries:BUWA.Germany,
Bio-Rad Laboratories Inc manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials.

Bio-Rad Laboratories Inc was founded in 1952 and incorporated in 1957. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates in two industry segments designated as Life Science and Clinical Diagnostics. Life science is the study of the characteristics, behavior, and structure of living organisms and their component systems. Life Science segment is at the forefront of discovery, creating tools to answer complex biological questions. The Company is engaged in developing, manufacturing and marketing a range of more than 5,000 reagents, apparatus and laboratory instruments that serve a wide customer base. Many of its products are used in established research techniques, biopharmaceutical production processes and food testing regimes. These techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and bacteria within a laboratory or production setting. Its main life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products currently address specific niches within the in vitro diagnostics (IVD) test market. It supplies more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test market. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient's tissue, blood or urine. Its products consist of reagents, instruments and software, typically provided to its customers as an integrated package to allow them to generate reproducible test results. Its main clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion laboratories and physician office laboratories. The Company owns numerous U.S. and international patents and patent licenses. Each of the Company's segments maintains a sales force to sell its products on a direct basis. Major competitors in the clinical diagnostic segment include Roche, Abbott Laboratories (Diagnostic Division), Siemens Medical Diagnostics Solutions (formerly Dade-Behring, Diagnostics Products Corporation, and Bayer Diagnostics), Beckman Coulter, Becton-Dickinson, bioMérieux, Johnson & Johnson (Ortho Clinical Diagnostics), Thermo Fisher, Tosoh, Immucor, Cepheid, and DiaSorin. The Company's operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissio

Ratios

vs
industry
vs
history
P/E(ttm) 49.11
BIO's P/E(ttm) is ranked lower than
72% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.60 vs. BIO: 49.11 )
Ranked among companies with meaningful P/E(ttm) only.
BIO' s P/E(ttm) Range Over the Past 10 Years
Min: 13.66  Med: 21.91 Max: 58.61
Current: 49.11
13.66
58.61
PE(NRI) 49.11
BIO's PE(NRI) is ranked lower than
72% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.47 vs. BIO: 49.11 )
Ranked among companies with meaningful PE(NRI) only.
BIO' s PE(NRI) Range Over the Past 10 Years
Min: 13.66  Med: 22.31 Max: 58.61
Current: 49.11
13.66
58.61
Price/Owner Earnings (ttm) 61.34
BIO's Price/Owner Earnings (ttm) is ranked lower than
76% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.42 vs. BIO: 61.34 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BIO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.69  Med: 19.99 Max: 134.78
Current: 61.34
9.69
134.78
P/B 1.83
BIO's P/B is ranked higher than
79% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. BIO: 1.83 )
Ranked among companies with meaningful P/B only.
BIO' s P/B Range Over the Past 10 Years
Min: 1.45  Med: 1.82 Max: 3.02
Current: 1.83
1.45
3.02
P/S 2.36
BIO's P/S is ranked higher than
60% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. BIO: 2.36 )
Ranked among companies with meaningful P/S only.
BIO' s P/S Range Over the Past 10 Years
Min: 0.87  Med: 1.56 Max: 2.37
Current: 2.36
0.87
2.37
PFCF 60.98
BIO's PFCF is ranked lower than
89% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.45 vs. BIO: 60.98 )
Ranked among companies with meaningful PFCF only.
BIO' s PFCF Range Over the Past 10 Years
Min: 9.61  Med: 24.59 Max: 469.08
Current: 60.98
9.61
469.08
POCF 25.38
BIO's POCF is ranked lower than
73% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. BIO: 25.38 )
Ranked among companies with meaningful POCF only.
BIO' s POCF Range Over the Past 10 Years
Min: 7.48  Med: 13.05 Max: 45.73
Current: 25.38
7.48
45.73
EV-to-EBIT 29.40
BIO's EV-to-EBIT is ranked lower than
65% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.20 vs. BIO: 29.40 )
Ranked among companies with meaningful EV-to-EBIT only.
BIO' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.4  Med: 13.1 Max: 29.5
Current: 29.4
8.4
29.5
EV-to-EBITDA 15.26
BIO's EV-to-EBITDA is ranked higher than
52% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.73 vs. BIO: 15.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6  Med: 9 Max: 15.9
Current: 15.26
6
15.9
Shiller P/E 35.33
BIO's Shiller P/E is ranked higher than
66% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 42.43 vs. BIO: 35.33 )
Ranked among companies with meaningful Shiller P/E only.
BIO' s Shiller P/E Range Over the Past 10 Years
Min: 19.56  Med: 27.92 Max: 42.78
Current: 35.33
19.56
42.78
Current Ratio 4.40
BIO's Current Ratio is ranked higher than
76% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. BIO: 4.40 )
Ranked among companies with meaningful Current Ratio only.
BIO' s Current Ratio Range Over the Past 10 Years
Min: 1.87  Med: 3.05 Max: 4.52
Current: 4.4
1.87
4.52
Quick Ratio 3.08
BIO's Quick Ratio is ranked higher than
68% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. BIO: 3.08 )
Ranked among companies with meaningful Quick Ratio only.
BIO' s Quick Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.3 Max: 3.45
Current: 3.08
1.22
3.45
Days Inventory 206.35
BIO's Days Inventory is ranked lower than
85% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.85 vs. BIO: 206.35 )
Ranked among companies with meaningful Days Inventory only.
BIO' s Days Inventory Range Over the Past 10 Years
Min: 151.29  Med: 169.37 Max: 206.35
Current: 206.35
151.29
206.35
Days Sales Outstanding 65.91
BIO's Days Sales Outstanding is ranked lower than
53% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. BIO: 65.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.37  Med: 70.75 Max: 89.45
Current: 65.91
63.37
89.45

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.00
BIO's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. BIO: -1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.3  Med: -1.1 Max: -0.2
Current: -1
-1.3
-0.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 8.73
BIO's Price/Net Current Asset Value is ranked higher than
50% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.50 vs. BIO: 8.73 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.86  Med: 6.61 Max: 95.94
Current: 8.73
2.86
95.94
Price/Tangible Book 2.54
BIO's Price/Tangible Book is ranked higher than
78% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.65 vs. BIO: 2.54 )
Ranked among companies with meaningful Price/Tangible Book only.
BIO' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.14  Med: 2.78 Max: 6.43
Current: 2.54
1.14
6.43
Price/Projected FCF 1.51
BIO's Price/Projected FCF is ranked higher than
67% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. BIO: 1.51 )
Ranked among companies with meaningful Price/Projected FCF only.
BIO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.78  Med: 1.25 Max: 17.2
Current: 1.51
0.78
17.2
Price/Median PS Value 1.51
BIO's Price/Median PS Value is ranked lower than
79% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. BIO: 1.51 )
Ranked among companies with meaningful Price/Median PS Value only.
BIO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 0.9 Max: 1.52
Current: 1.51
0.24
1.52
Price/Graham Number 2.35
BIO's Price/Graham Number is ranked higher than
67% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. BIO: 2.35 )
Ranked among companies with meaningful Price/Graham Number only.
BIO' s Price/Graham Number Range Over the Past 10 Years
Min: 0.69  Med: 1.65 Max: 4.42
Current: 2.35
0.69
4.42
Earnings Yield (Greenblatt) (%) 3.40
BIO's Earnings Yield (Greenblatt) (%) is ranked higher than
71% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. BIO: 3.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.38  Med: 7.6 Max: 11.9
Current: 3.4
3.38
11.9
Forward Rate of Return (Yacktman) (%) -6.94
BIO's Forward Rate of Return (Yacktman) (%) is ranked lower than
83% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.43 vs. BIO: -6.94 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BIO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -6.94  Med: 10.8 Max: 22.4
Current: -6.94
-6.94
22.4

More Statistics

Revenue (TTM) (Mil) $2,028
EPS (TTM) $ 3.30
Beta0.74
Short Percentage of Float6.15%
52-Week Range $122.03 - 162.97
Shares Outstanding (Mil)29.42
» More Articles for BIO

Headlines

Articles On GuruFocus.com

More From Other Websites
ETF’s with exposure to Bio-Rad Laboratories, Inc. : September 8, 2016 Sep 08 2016
BIO RAD LABORATORIES INC Financials Aug 11 2016
Illumina and FlowJo, LLC Partner to Develop and Co-Market a Software Solution for Single Cell... Aug 10 2016
ETF’s with exposure to Bio-Rad Laboratories, Inc. : August 9, 2016 Aug 09 2016
Bio-Rad Laboratories, Inc. :BIO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 Aug 08 2016
BIO RAD LABORATORIES INC Files SEC form 10-Q, Quarterly Report Aug 05 2016
Edited Transcript of BIO earnings conference call or presentation 3-Aug-16 9:00pm GMT Aug 03 2016
Bio-Rad Reports Second-Quarter 2016 Financial Results Aug 03 2016
Bio-Rad posts 2Q profit Aug 03 2016
Bio-Rad posts 2Q profit Aug 03 2016
Bio-Rad posts 2Q profit Aug 03 2016
BIO RAD LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 03 2016
Bio-Rad Reports Second-Quarter 2016 Financial Results Aug 03 2016
Q2 2016 Bio Rad Laboratories Inc Earnings Release - After Market Close Aug 03 2016
Medical Product Stocks Earnings Preview for Aug 3: BIO, CSII & More Aug 02 2016
Bio-Rad Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : BIO-US : July... Jul 27 2016
Bio-Rad Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : BIO-US : July... Jul 13 2016
Bio-Rad to Report Second-Quarter 2016 Financial Results Wednesday, August 3, 2016 Jul 11 2016
Bio-Rad to Report Second-Quarter 2016 Financial Results Wednesday, August 3, 2016 Jul 11 2016
ETF’s with exposure to Bio-Rad Laboratories, Inc. : June 20, 2016 Jun 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)